Long non-coding RNA XIST expression as a prognostic factor in human cancers: A meta-analysis

Int J Biol Markers. 2019 Dec;34(4):327-333. doi: 10.1177/1724600819873010. Epub 2019 Sep 30.

Abstract

A large number of literature has shown that high expression of X inactive-specific transcript (XIST) is associated with poor prognosis and metastasis of cancer in patients. However, most of this literature is limited by the small sample sizes and discrete outcomes. Therefore, a meta-analysis was performed to investigate the relation between XIST expression and tumor node metastasis (TNM) stage, lymph node metastasis, distant metastasis, and overall survival of cancer patients. We searched for literature in PubMed, Embase, and Web of Science. The pooled hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to evaluate the association of XIST expression with prognosis and clinicopathological characteristics of cancer patients. Finally, a total of 14 articles involving 1123 patients were included in this meta-analysis. The results suggested that high expression of XIST has a significant relationship with a relatively poor overall survival for patients with malignant tumors (HR 1.82; 95% CI 1.32, 2.52; P = 0.0003). Moreover, high expression of XIST was significantly associated with poor TNM stage (OR 3.64; 95% CI 2.62, 5.07; P < 0.0001), lymph node metastasis (OR 2.39; 95% CI 1.65, 3.46; P < 0.0001) and distant metastasis (OR 2.84; 95% CI 1.90, 4.23; P < 0.0001). In conclusion, high expression of lncRNA XIST may be a predictive factor of poor prognosis in human cancers.

Keywords: Long non-coding RNA; XIST; cancer; meta-analysis.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Humans
  • Neoplasms / genetics*
  • Neoplasms / pathology
  • Prognosis
  • RNA, Long Noncoding / genetics*

Substances

  • RNA, Long Noncoding
  • XIST non-coding RNA